

Adding value to your assets, our aim.

Finding a use for existing advanced small molecules in the therapeutic treatment of atopic dermatitis, psoriasis, actinic keratosis, acne, and related dermatological diseases.



Our aim

We are looking for

- Compounds addressing a specific target or pathway in a selective manner with a scientific rationale that supports their use on one or more indications of interest
- More specifically, Research compounds that have shown a good potency and an acceptable pharmacokinetic profile or Development compounds that have shown a good human safety profile

Who is this for

This call is addressed to scientists affiliated to Universities, Research Centers, Start-ups, Biotechs, and Pharma companies all over the world.

Collaboration framework

- Submitted compounds will be profiled on key dermatological assays *in vitro* and *in vivo*
- Intellectual property rights remain with the applicant
 - No need to disclose the chemical structure of your compound
 - All data and results generated will be treated as strictly confidential and will only be used to decide about future collaboration options
 - You will be the owner of the results obtained
 - We expect you not to patent, register, or otherwise communicate to any third party the results we generated whilst we are collaborating
- A specific contact person to help you should you have questions

Collaboration process

- Proposal submission
 - The first step is for you to create an account in AlmirallShare Innovation platform which is a secure site to store and manage your proposals
 - You can submit your proposal at any time

- All the initial information provided under the proposal should be non-confidential. Please do not reveal the chemical structure of your compound, even if it is published
- Please include an outline of your proposal (max. 300 words) and a detailed description of your advanced compound properties, including at least biological data such as target and affinities (IC50, Ki, etc...), and available ADME data
- Submissions will be handled following all applicable local compliance rules
- Proposal evaluation and selection
 - A team of Amirall scientific experts will evaluate your proposal
 - You will receive in writing Amirall's decision regarding your proposal within 4-8 weeks after submission
 - If your proposal has been selected, A member of the Shared Innovation Team will reach out to you to initiate a Material Transfer Agreement (MTA)
 - Compounds will be tested in a pre-agreed panel of relevant cellular assays and in vivo disease models within a period of 4-6 months, starting upon MTA signature. This panel could be complemented with other assays, such as physicochemical properties and pharmacokinetic studies.

Join us in our journey
 Amirall, Science and you
Shared Innovation Team